CD8+ and CD4+ T cell activation induced by administration of TCL-loaded cDC1s contributes to reduced tumor progression and even remission of established tumors derived from the three cancer cell lines B16-OVA, B16/F10 and MC38, the latter two not expressing exogenous Ags. Here, CD8A is linked to neoplasm.